Co-Ceo — Business / Cofounder
CurrentIbex has a portfolio of therapeutic antibodies, gene therapy, and stem cell programs. Additionally, Ibex is developing diagnostic antibodies for IHC to increase the diagnostic reliability of biopsies. Unique to many early-stage biotechnology companies, Ibex engages in a diverse approach to research and development. Ibex strives to discover, validate, and produce potential solutions to a multitude of serious challenges facing human and ecological health by investing in exploratory projects and processes that may not have been validated within the public research community.